Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zai Lab Approved to Launch Tumor Treating Fields for Glioblastoma in China

publication date: May 13, 2020

Zai Lab of Shanghai announced China's NMPA approved Optune, a therapy known as Tumor Treating Fields, to treat glioblastoma (GBM). Optune uses electric fields tuned to specific frequencies to disrupt cell division. The therapy is approved in combination with temozolomide to treat patients with newly diagnosed GBM, and as a monotherapy in patients with recurrent GBM. In 2018, Zai paid $15 million upfront to in-license greater China rights to the Optune therapy from Novocure of Jersey. More details....

Stock Symbols: (NSDQ: ZLAB)  (NSDQ: NVCR)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here